Dechert is advising Mayoly Spindler, a French family-owned and independent pharmaceutical group, in connection with its exclusive negotiations with Ipsen to acquire its consumer healthcare branch, which includes established brands such as Smecta®, Forlax® and Tanakan®, distributed in more than 80 countries.
In addition to the support of the historical banking partners, Capza and Caravelle, two French and European financial partners specialized in operations of this scale, will supply part of the funds required to complete this transaction, by acquiring a minority stake in the combined entity. Dechert also advises Mayoly Spindler in the context of this equity investment.
This transaction will enable Mayoly Spindler to strengthen its expertise in gastroenterology, where it is a leader in the treatment of irritable bowel syndrome.
The Dechert team advising Mayoly Spindler is led by partners Alain Decombe and Ermine Bolot. The members of the team include: corporate/M&A partner Ermine Bolot, associates Pierre-Henri Brieau, Yan Boistay, Mathilde Duchamp; private equity (on the fund investment) national partner Delphin Boucher and associate Dahila Ibourichene; antitrust partners Mélanie Thill-Tayara and Laurence Bary and associate Pénélope Agosta; regulatory partner Sophie Pelé and associates Jessica Garestier and Margaux Lasseigne; and Labour partner Philippe Thomas and associate Viviane Valilou.
About Dechert
Dechert is a leading global law firm with 22 offices around the world. We advise on matters and transactions of the greatest complexity, bringing energy, creativity and efficient management of legal issues to deliver commercial and practical advice for clients.
Related Professionals
